Patrick Still - Potential of Plant-Derived Natural Products in the Treatment of Leukemia and Lymphoma.

Document created by Patrick Still on Aug 22, 2014
Version 1Show Document
  • View in full screen mode

  Publication Details (including relevant citation   information):

David M. Lucas, Patrick C. Still, Lynette Bueno Pérez, Michael R. Grever, and A. Douglas Kinghorn (2010). Potential of Plant-Derived Natural Products in the Treatment of Leukemia and Lymphoma. Current Drug Targets11: 812-822. (Invited review article)

  Abstract:

  Hematologic malignancies account for a substantial percentage of   cancers worldwide, and the heterogeneity and biological   characteristics of leukemias and lymphomas present unique   therapeutic challenges. Although treatment options exist for most   of these diseases, many types remain incurable and the emergence   of drug resistance is pervasive. Thus, novel treatment approaches   are essential to improve outcome. Nearly half of the agents used   in cancer therapy today are either natural products or   derivatives of natural products. The enormous chemical diversity   in nature, coupled with millennia of biological selection, has   generated a vast and underexplored reservoir of unique chemical   structures with biologic activity. This review will describe the   investigation and application of natural products derived from   higher plants in the treatment of leukemia and lymphoma and the   rationale behind these efforts. In addition to the approved vinca   alkaloids and the epipodophyllotoxin derivatives, a number of   other plant compounds have shown promise in clinical trials and   in preclinical investigations. In particular, we will focus on   the discovery and biological evaluation of the plant-derived   agent silvestrol, which shows potential for additional   development as a new therapeutic agent for B-cell malignancies   including chronic lymphocytic leukemia.

  Address (URL): http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2892601/

 

Attachments

    Outcomes